Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma and liposaroma (NCT03886311).

Authors
Category Primary study
Conference2025 ASCO Annual Meeting I
Year 2025
This article has no abstract
Epistemonikos ID: 56b5702f666c212efcb6de57e0bd75228f65ec45
First added on: Sep 03, 2025